Free Trial
NASDAQ:VCEL

Vericel (VCEL) Stock Price, News & Analysis

Vericel logo
$33.67 +0.12 (+0.36%)
Closing price 04:00 PM Eastern
Extended Trading
$34.24 +0.57 (+1.70%)
As of 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vericel Stock (NASDAQ:VCEL)

Key Stats

Today's Range
$33.36
$34.56
50-Day Range
$33.55
$42.55
52-Week Range
$33.09
$63.00
Volume
1.13 million shs
Average Volume
508,588 shs
Market Capitalization
$1.70 billion
P/E Ratio
280.61
Dividend Yield
N/A
Price Target
$60.40
Consensus Rating
Buy

Company Overview

Vericel Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

VCEL MarketRank™: 

Vericel scored higher than 47% of companies evaluated by MarketBeat, and ranked 617th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Vericel has only been the subject of 2 research reports in the past 90 days.

  • Read more about Vericel's stock forecast and price target.
  • Earnings Growth

    Earnings for Vericel are expected to grow by 214.29% in the coming year, from $0.14 to $0.44 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vericel is 280.61, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 271.86.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vericel is 280.61, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 83.02.

  • Price to Book Value per Share Ratio

    Vericel has a P/B Ratio of 5.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Vericel's valuation and earnings.
  • Percentage of Shares Shorted

    11.16% of the outstanding shares of Vericel have been sold short.
  • Short Interest Ratio / Days to Cover

    Vericel has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Vericel has recently increased by 1.26%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Vericel does not currently pay a dividend.

  • Dividend Growth

    Vericel does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.16% of the outstanding shares of Vericel have been sold short.
  • Short Interest Ratio / Days to Cover

    Vericel has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Vericel has recently increased by 1.26%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Vericel has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Vericel this week, compared to 6 articles on an average week.
  • Search Interest

    5 people have searched for VCEL on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Vericel to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vericel insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.20% of the stock of Vericel is held by insiders.

  • Read more about Vericel's insider trading history.
Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VCEL Stock News Headlines

Did you spot this in the Oval Office last week?
When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to President Trump. But many viewers missed an even more important moment in that 30-second clip. One that unmistakably singled out what Futurist Eric Fry calls "possibly the best AI investment anyone could make right now." Eric believes this little-known partner to Apple could go crazy over the next 12-24 months, potentially leaving well-known AI stocks like Nvidia, Microsoft and Google in the dust.tc pixel
Analysts Set Vericel Corporation (NASDAQ:VCEL) PT at $60.33
11 Best Small-Cap Growth Stocks to Buy Right Now
Vericel (VCEL) Receives a Buy from Canaccord Genuity
Vericel Q2 Revenue Jumps 20%
See More Headlines

VCEL Stock Analysis - Frequently Asked Questions

Vericel's stock was trading at $54.91 on January 1st, 2025. Since then, VCEL shares have decreased by 38.7% and is now trading at $33.67.

Vericel Corporation (NASDAQ:VCEL) issued its earnings results on Thursday, July, 31st. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.03. Vericel's revenue was up 20.1% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of Vericel include Brown Capital Management LLC (5.57%), Conestoga Capital Advisors LLC (4.89%), State Street Corp (4.83%) and Invesco Ltd. (3.95%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Paul K Wotton, Robert L Md Zerbe, Joseph Anthony Mara Jr, Steven C Gilman, Jonathan Siegal, Michael Halpin and Sean C Flynn.
View institutional ownership trends
.

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Palo Alto Networks (PANW) and Netflix (NFLX).

Company Calendar

Last Earnings
7/31/2025
Today
9/04/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VCEL
CIK
887359
Employees
300
Year Founded
1989

Price Target and Rating

High Price Target
$67.00
Low Price Target
$51.00
Potential Upside/Downside
+79.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.12
Trailing P/E Ratio
280.61
Forward P/E Ratio
240.50
P/E Growth
N/A
Net Income
$10.36 million
Net Margins
2.85%
Pretax Margin
2.91%
Return on Equity
2.47%
Return on Assets
1.69%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.97
Quick Ratio
4.56

Sales & Book Value

Annual Sales
$237.22 million
Price / Sales
7.16
Cash Flow
$0.29 per share
Price / Cash Flow
116.36
Book Value
$6.08 per share
Price / Book
5.54

Miscellaneous

Outstanding Shares
50,460,000
Free Float
46,827,000
Market Cap
$1.70 billion
Optionable
Optionable
Beta
1.33

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:VCEL) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners